Minerva Neurosciences Inc (NASDAQ:NERV)

0.835
Delayed Data
As of 3:59pm ET
 -0.0079 / -0.94%
Today’s Change
0.79
Today|||52-Week Range
3.69
+4.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$38.1M

Company Description

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Waltham, MA.

Contact Information

Minerva Neurosciences, Inc.
1601 Trapelo Road
Waltham Massachusetts 02451
P:(617) 600-7373
Investor Relations:
(617) 600-7376

Employees

Shareholders

Mutual fund holders40.10%
Individual stakeholders28.21%
Other institutional18.58%

Top Executives

Rémy Henri LuthringerExecutive Chairman & Chief Executive Officer
Geoff RacePresident
Joseph ReillyChief Operating Officer & Senior Vice President
Fred AhlholmChief Financial Officer & Senior VP-Finance
Michael DavidsonChief Medical Officer